Drug
Atumelnant
Atumelnant is a pharmaceutical drug with 5 clinical trials. Currently 4 active trials ongoing. Historical success rate of 100.0%.
Total Trials
5
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 1 completed trials
Completion Rate
100%(1/1)
Active Trials
4(80%)
Results Posted
0%(0 trials)
Phase Distribution
Ph phase_2
1
20%
Ph phase_1
3
60%
Ph phase_3
1
20%
Phase Distribution
3
Early Stage
1
Mid Stage
1
Late Stage
Phase Distribution5 total trials
Phase 1Safety & dosage
3(60.0%)
Phase 2Efficacy & side effects
1(20.0%)
Phase 3Large-scale testing
1(20.0%)
Highest Phase Reached
Phase 3Trial Status & Enrollment
Completion Rate
100.0%
1 of 1 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
4
trials recruiting
Total Trials
5
all time
Status Distribution
Active(4)
Completed(1)
Detailed Status
Recruiting4
Completed1
Development Timeline
Analytics
Development Status
Total Trials
5
Active
4
Success Rate
100.0%
Most Advanced
Phase 3
Trials by Phase
Phase 13 (60.0%)
Phase 21 (20.0%)
Phase 31 (20.0%)
Trials by Status
recruiting480%
completed120%
Recent Activity
4 active trials
Showing 5 of 5
recruitingphase_1
Drug-Drug Interaction Study of Atumelnant in Healthy Participants
NCT07570082
recruitingphase_3
A Study to Evaluate Atumelnant in Adults With Congenital Adrenal Hyperplasia
NCT07144163
recruitingphase_2
A Study in Pediatric Participants With Congenital Adrenal Hyperplasia (Balance-CAH)
NCT07159841
completedphase_1
A Study to Assess Pharmacokinetics, Safety, and Tolerability of Atumelnant in Healthy Japanese and Caucasian Participants
NCT07221084
recruitingphase_1
A Study to Evaluate the Safety and PK of CRN04894 for the Treatment of Cushing's Syndrome
NCT05804669
Clinical Trials (5)
Showing 5 of 5 trials
NCT07570082Phase 1
Drug-Drug Interaction Study of Atumelnant in Healthy Participants
NCT07144163Phase 3
A Study to Evaluate Atumelnant in Adults With Congenital Adrenal Hyperplasia
NCT07159841Phase 2
A Study in Pediatric Participants With Congenital Adrenal Hyperplasia (Balance-CAH)
NCT07221084Phase 1
A Study to Assess Pharmacokinetics, Safety, and Tolerability of Atumelnant in Healthy Japanese and Caucasian Participants
NCT05804669Phase 1
A Study to Evaluate the Safety and PK of CRN04894 for the Treatment of Cushing's Syndrome
All 5 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 5